FILTER

FILTERED INTERVIEW RESULTS

Chris Garabedian

CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND

"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."

Mining

United States

Jeff Olsen

CEO, BOART LONGYEAR

"I believe the increased drilling activity will continue into 2023, and we are anticipating strong business for the foreseeable future."

Mining

United States

Keith Jones

GENERAL MANAGER, SMALL MINE DEVELOPMENT (SMD)

"We are open to working anywhere in the US where there are hard rock, metal, or non-metal, underground mines."

United States

Pharma & Life Sciences

Tom Wilson

GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE

"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."

United States

Pharma & Life Sciences

Fabrice Panza

MANAGER GLOBAL COOL CHAIN SOLUTIONS, ETIHAD CARGO

"Etihad Cargo’s PharmaLife product has exponentially grown over the past year, and growth will trigger more physical ties between US and UAE."

Mining

United States

Dagny Odell

OWNER, PRACTICAL MINING

"If you think about the end use and reclamation requirements early on and incorporate solutions early, it makes the project much more efficient and improves the final environmental outcome."

Mining

United States

Mark Compton

EXECUTIVE DIRECTOR, AMERICAN EXPLORATION & MINING ASSOCIATION (AEMA)

"Put simply, without permitting reform it will be impossible to meet our nation’s mineral needs."

United States

Pharma & Life Sciences

James Sapirstein

CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA

“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”

United States

Pharma & Life Sciences

Kendalle O’Connell

CEO AND PRESIDENT, MASSBIO

"In 2022, Massachusetts received 25% of all biopharma VC funding in the US. We are seeing new clusters emerge outside the traditional hubs of Kendall Square and Boston."

United States

Pharma & Life Sciences

Arda Ural

AMERICAS INDUSTRY MARKET LEADER, HEALTH SCIENCES & WELLNESS, EY USA

"We are going to help the industry digitalize, prepare for the innovation deficit due to expiring patents and improve strategies that lead to better M&A opportunities."